Key facts
- It has raised $73.0M; the latest was Grant ($1.4M) in Mar 2025.
- Notable investors include Innovate UK, F-Prime Capital, Amadeus Capital Partners, Meltwind Advisory, Jonathan Milner — 12 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for Constructive Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Constructive Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Constructive Bio
Operator of a biotechnology company intended to drive the next generation of bioprocesses and biopharmaceuticals. The company creates virus-resistant organisms and turns living cells into sustainable biofactories to realize sustainable materials and therapies to biosynthesize classes of enzymes, pharmaceuticals, and biomaterials, enabling biotech clients to re-program the genetic code and make natural molecules.
- Sector
- Healthcare
- HQ
- Cambridge, United Kingdom
- Founded
- 2021
- Employees
- 48
- Website
- constructive.bio/
- Ownership
- Privately Held (backing)
Constructive Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Constructive Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Constructive Bio in its N-PORT filings yet. We sweep new filings monthly.